Cholera vaccines are designed to prevent infection by Vibrio cholerae, the bacterium responsible for cholera, a diarrheal disease with the potential for severe dehydration and death if left untreated. Two main types of cholera vaccines are available: oral cholera vaccines (OCVs) and injectable cholera vaccines. OCVs, such as Dukoral and Shanchol, are administered orally and provide immunity against cholera by inducing an immune response in the gut. These vaccines offer some level of protection within a short time, making them suitable for use during outbreaks and in endemic areas. Injectable cholera vaccines, like Vaxchora, are administered as a single-dose oral vaccine and are primarily used for travelers to cholera-endemic regions. Cholera vaccines have contributed significantly to cholera control and prevention efforts, particularly in regions with inadequate sanitation and water infrastructure. However, vaccine availability, distribution, and access remain challenges in some areas affected by cholera outbreaks. Vaccination is complemented by other measures, such as improving water and sanitation infrastructure, to comprehensively address cholera transmission. Timely vaccination campaigns, particularly during outbreaks and in high-risk populations, are crucial in reducing the burden of cholera and preventing its spread.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States